|
1
|
Siegel RL, Ward EM and Jemal A: Trends in
colorectal cancer incidence rates in the United States by tumor
location and stage, 1992–2008. Cancer Epidemiol Biomarkers Prev.
21:411–416. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2017. CA Cancer J Clin. 60:277–300. 2015.
|
|
3
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chen W, Zheng R, Zhang S, Zeng H, Zuo T,
Xia C, Yang Z and He J: Cancer incidence and mortality in China in
2013: An analysis based on urbanization level. Chin J Cancer Res.
29:1–10. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Li J, Hou N, Faried A, Tsutsumi S and
Kuwano H: Inhibition of autophagy augments 5-fluorouracil
chemotherapy in human colon cancer in vitro and in vivo model. Eur
J Cancer. 46:1900–1909. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sanoff HK, Carpenter WR, Freburger J, Li
L, Chen K, Zullig LL, Goldberg RM, Schymura MJ and Schrag D:
Comparison of adverse events during 5-fluorouracil versus
5-fluorouracil/oxaliplatin adjuvant chemotherapy for stage III
colon cancer: A Population-based analysis. Cancer. 118:4309–4320.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cheah KY, Howarth GS, Bindon KA, Kennedy
JA and Bastian SEP: Low Molecular weight procyanidins from grape
seeds enhance the impact of 5-fluorouracil chemotherapy on Caco-2
human colon cancer cells. PLoS One. 9:e989212014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gao Y, Xiao X, Zhang C, Yu W, Guo W, Zhang
Z, Li Z, Feng X, Hao J, Zhang K, et al: Melatonin synergizes the
chemotherapeutic effect of 5-fluorouracil in colon cancer by
suppressing PI3K/AKT and NF-B/iNOS signaling pathways. J Pineal
Res. 622017.doi: 10.1111/jpi.12380.
|
|
9
|
Wang SF, Wu MY, Cai CZ, Li M and Lu JH:
Autophagy modulators from traditional Chinese medicine: Mechanisms
and therapeutic potentials for cancer and neurodegenerative
diseases. J Ethnopharmacol. 194:861–876. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ernst E: Traditional Chinese medicine for
cancer? Br J Cancer. 107:4052012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sun HY, Lee JH, Han YS, Yoon YM, Yun CW,
Kim JH, Song YS and Lee SH: Pivotal roles of ginsenoside Rg3 in
tumor apoptosis through regulation of reactive oxygen species.
Anticancer Res. 36:4647–4654. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tang YC, Zhang Y, Zhou J, Zhi Q, Wu MY,
Gong FR, Shen M, Liu L, Tao M, Shen B, et al: Ginsenoside Rg3
targets cancer stem cells and tumor angiogenesis to inhibit
colorectal cancer progression in vivo. Int J Oncol.
52:127–138. 2018.PubMed/NCBI
|
|
13
|
Wang J, Tian L, Khan MN, Zhang L, Chen Q,
Zhao Y, Yan Q, Fu L and Liu J: Ginsenoside Rg3 sensitizes hypoxic
lung cancer cells to cisplatin via blocking of NF-κB mediated
epithelial-mesenchymal transition and sternness. Cancer Lett.
415:73–85. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Joo E, Ha YW and Kim YS: Abstract #LB-23:
Molecular mechanisms of ginsenoside Rg3 related to apoptosis in
human lung and pancreatic adenocarcinomas. Cancer Res:. 69:LB–23.
2009.
|
|
15
|
Kim BJ, Nah SY, Jeon JH, So I and Kim SJ:
Transient receptor potential Melastatin 7 channels are involved in
Ginsenoside Rg3-induced apoptosis in gastric cancer cells. Basic
Clin Pharmacol. 109:233–239. 2011. View Article : Google Scholar
|
|
16
|
Kim SM, Lee SY, Cho JS, Son SM, Choi SS,
Yun YP, Yoo HS, Yoon DY, Oh KW, Han SB and Hong JT: Combination of
ginsenoside Rg3 with docetaxel enhances the susceptibility of
prostate cancer cells via inhibition of NF-kappa B. Eur J
Pharmacol. 631:1–9. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yuan HD, Quan HY, Zhang Y, Kim SH and
Chung SH: 20(S)-Ginsenoside Rg3-induced apoptosis in HT-29 colon
cancer cells is associated with AMPK signaling pathway. Mol Med
Rep. 3:825–831. 2010.PubMed/NCBI
|
|
18
|
Liu TG, Huang Y, Cui DD, Huang XB, Mao SH,
Ji LL, Song HB and Yi C: Inhibitory effect of ginsenoside Rg3
combined with gemcitabine on angiogenesis and growth of lung cancer
in mice. BMC Cancer. 9:2502009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sun MY, Ye Y, Xiao L, Duan XY, Zhang YM
and Zhang H: Anticancer effects of ginsenoside Rg3 (Review). Int J
Mol Med. 39:507–518. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Longley DB, Harkin DP and Johnston PG:
5-Fluorouracil: Mechanisms of action and clinical strategies. Nat
Rev Cancer. 3:330–338. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hokmabady L, Raissi H and Khanmohammadi A:
Interactions of the 5-fluorouracil anticancer drug with DNA
pyrimidine bases: A detailed computational approach. Struct Chem.
27:487–504. 2016. View Article : Google Scholar
|
|
22
|
Rateesh S, Luis SA, Luis CR, Hughes B and
Nicolae M: Myocardial infarction secondary to 5-fluorouracil: Not
an absolute contraindication to rechallenge? Int J Cardiol.
172:e331–e333. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Shan X, Aziz F, Tian LL, Wang XQ, Yan Q
and Liu JW: Ginsenoside Rg3-induced EGFR/MAPK pathway deactivation
inhibits melanoma cell proliferation by decreasing FUT4/LeY
expression. Int J Oncol. 46:1667–1676. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Luo Y, Zhang P, Zeng HQ, Lou SF and Wang
DX: Ginsenoside Rg3 induces apoptosis in human multiple myeloma
cells via the activation of Bcl-2-associated X protein. Mol Med
Rep. 12:3557–3562. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cardone MH, Roy N, Stennicke HR, Salvesen
GS, Franke TF, Stanbridge E, Frisch S and Reed JC: Regulation of
cell death protease caspase-9 by phosphorylation. Science.
282:1318–1321. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hassan M, Watari H, AbuAlmaaty A, Ohba Y
and Sakuragi N: Apoptosis and molecular targeting therapy in
cancer. Biomed Res Int. 2014:1508452014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Boward B, Wu TM and Dalton S: Concise
review: Control of cell fate through cell cycle and pluripotency
networks. Stem Cells. 34:1427–1436. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Harashima H, Dissmeyer N and Schnittger A:
Cell cycle control across the eukaryotic kingdom. Trends in Cell
Biol. 23:345–356. 2013. View Article : Google Scholar
|
|
29
|
Lamb J, Ramaswamy S, Ford HL, Contreras B,
Martinez RV, Kittrell FS, Zahnow CA, Patterson N, Golub TR and Ewen
ME: A mechanism of cyclin D1 action encoded in the patterns of gene
expression in human cancer. Cell. 114:323–334. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Thiery JP, Acloque H, Huang RYJ and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yang J and Weinberg RA:
Epithelial-mesenchymal transition: At the crossroads of development
and tumor metastasis. Dev Cell. 14:818–829. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kim YJ, Choi WI, Jeon BN, Choi KC, Kim K,
Kim TJ, Ham J, Jang HJ, Kang KS and Ko H: Stereospecific effects of
ginsenoside 20-Rg3 inhibits TGF-β1-induced epithelial-mesenchymal
transition and suppresses lung cancer migration, invasion and
anoikis resistance. Toxicology. 322:23–33. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Pan XY, Guo H, Han J, Hao F, An Y, Xu Y,
Xiaokaiti Y, Pan Y and Li XJ: Ginsenoside Rg3 attenuates cell
migration via inhibition of aquaporin 1 expression in PC-3M
prostate cancer cells. Eur J Pharmacol. 683:27–34. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lee SG, Kang YJ and Nam JO:
Anti-metastasis effects of Ginsenoside Rg3 in B16F10 cells. J
Microbiol Biotechnol. 25:1997–2006. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Cheng L, Luo S, Jin C, Ma H, Zhou H and
Jia L: FUT family mediates the multidrug resistance of human
hepatocellular carcinoma via the PI3K/Akt signaling pathway. Cell
Death Dis. 4:e9232013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Adams JR, Schachter NF, Liu JC,
Zacksenhaus E and Egan SE: Elevated PI3K signaling drives multiple
breast cancer subtypes. Oncotarget. 2:435–447. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Jiang QG, Li TY, Liu DN and Zhang HT:
PI3K/Akt pathway involving into apoptosis and invasion in human
colon cancer cells LoVo. Mol Biol Rep. 41:3359–3367. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Fu XQ, Feng JR, Zeng D, Ding Y, Yu CS and
Yang B: PAK4 confers cisplatin resistance in gastric cancer cells
via PI3K/Akt- and MEKERK-dependent pathways. Biosci Rep.
34:e000942014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Stafman LL and Beierle EA: Cell
proliferation in neuroblastoma. Cancers (Basel). 8:132016.
View Article : Google Scholar
|
|
40
|
Ma H, Cheng L, Hao K, Li Y, Song X, Zhou H
and Jia L: Reversal effect of ST6GAL 1 on multidrug resistance in
human leukemia by regulating the PI3K/Akt pathway and the
expression of P-gp and MRP1. PLoS One. 9:e851132014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Hennessy BT, Smith DL, Ram PT, Lu YL and
Mills GB: Exploiting the PI3K/AKT pathway for cancer drug
discovery. Nat Rev Drug Disc. 4:988–1004. 2005. View Article : Google Scholar
|
|
42
|
Shi F, Liao X, Yao LI, et al: Plant
polyphenols exert anti-tumor activity by the PI3K/Akt signaling
pathway: A Review. 2016.
|
|
43
|
Wang H, Zhao L, Zhu LT, Wang Y, Pan D, Yao
J, You QD and Guo QL: Wogonin reverses hypoxia resistance of human
colon cancer HCT116 cells via downregulation of HIF-1α and
Glycolysis, by inhibiting PI3K/Akt signaling pathway. Mol Carcinog.
53 (Suppl 1):E107–E118. 2014. View Article : Google Scholar : PubMed/NCBI
|
